CD274 and neoplasm: In addition to PD-L1 expression in tumor tissue, other factors in the tumor microenvironment such as tumor mutation burden, tumor-infiltrating lymphocytes, and hypoxia have been reported as predictors of therapeutic response to ICIs, including nivolumab [22,55,56].